ALBO:NSD-Albireo Pharma, Inc (USD)

COMMON STOCK | Biotechnology | NSD

Last Closing Price

USD 33.87

Change

-0.60 (-1.74)%

Market Cap

USD 0.66B

Volume

0.24M

Average Target Price

USD 70.00 (+106.67%)
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

Albireo Pharma, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel bile acid modulators to treat orphan pediatric liver diseases and gastrointestinal disorders. Its lead product candidate is odevixibat, an ileal bile acid transporter (IBAT) inhibitor that is in phase III clinical trial for treating patients with progressive familial intrahepatic cholestasis, as well as for treating biliary atresia, alagille syndrome, and other cholestatic liver diseases. The company is also developing Elobixibat for the treatment of chronic constipation and other functional diseases, and nonalcoholic steatohepatitis; and A3384 for the treatment of gastrointestinal diseases. It has a license agreement with EA Pharma for the development and commercialization of elobixibat. Albireo Pharma, Inc. is headquartered in Boston, Massachusetts.

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-03-04 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
VRTX Vertex Pharmaceuticals Incorpo..

-0.65 (-0.31%)

USD54.19B 20.26 15.08
MRNA Moderna, Inc

+1.08 (+0.82%)

USD52.46B N/A N/A
REGN Regeneron Pharmaceuticals, Inc

+2.65 (+0.59%)

USD47.86B 14.64 11.87
ALXN Alexion Pharmaceuticals, Inc

+0.27 (+0.18%)

USD32.58B 54.48 33.22
BGNE BeiGene, Ltd

-15.33 (-5.03%)

USD29.17B N/A N/A
SGEN Seagen Inc

-2.48 (-1.68%)

USD26.80B 43.90 37.70
RPRX Royalty Pharma plc

-1.23 (-2.82%)

USD26.45B 22.60 14.17
BNTX BioNTech SE

-2.10 (-2.16%)

USD25.28B -99,999.99 N/A
GMAB Genmab A/S

-1.63 (-5.01%)

USD22.05B 26.59 3.17
IMMU Immunomedics, Inc

N/A

USD20.31B N/A N/A

ETFs Containing ALBO

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -9.70% 27% F 16% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -9.70% 27% F 16% F
Trailing 12 Months  
Capital Gain 51.41% 65% D 67% D+
Dividend Return N/A N/A N/A N/A N/A
Total Return 51.41% 65% D 67% D+
Trailing 5 Years  
Capital Gain 222.57% 83% B 83% B
Dividend Return N/A N/A N/A N/A N/A
Total Return 222.57% 83% B 82% B-
Average Annual (5 Year Horizon)  
Capital Gain 28.62% 66% D 80% B-
Dividend Return N/A N/A N/A N/A N/A
Total Return 28.62% 65% D 80% B-
Risk Return Profile  
Volatility (Standard Deviation) 49.38% 57% F 28% F
Risk Adjusted Return 57.95% 83% B 76% C
Market Capitalization 0.66B 62% D- 56% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A N/A N/A
Price/Book Ratio 3.14 73% C 51% F
Price / Cash Flow Ratio -6.52 41% F 68% D+
EV/EBITDA N/A N/A N/A N/A N/A
Management Effectiveness  
Return on Equity -78.45% 38% F 15% F
Return on Invested Capital -67.79% 42% F 14% F
Return on Assets -26.70% 51% F 15% F
Debt to Equity Ratio 5.31% 68% D+ 82% B-
Technical Ratios  
Short Ratio 7.65 20% F 10% F
Short Percent 8.38% 35% F 23% F
Beta 1.62 40% F 25% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

What to not like:
Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector